Pegvisomant As Add-On to Somatostatin Analogue

Home , Pegvisomant

research highlights pharmacotherapy pegvisomant as add-on to somatostatin analogue therapy addition of around 60 mg pegvisomant they received a monthly 120 mg dose of weekly to somatostatin analogue the ssa lanreotide. Patients biochemically (ssa) therapy has an equal efficacy as uncontrolled after this period (n = 57) pegvisomant monotherapy, enabling a dose entered a 28-week coadministration period, reduction in weekly pegvisomant of more receiving 120 mg lanreotide per month than 50%, according to a new study in the plus pegvisomant (60 mg once weekly, European Journal of Endocrinology. adapted every 8 weeks based on iGF-1 “Combining somatostatin analogues levels to 40–80 mg once weekly or 40 mg or and pegvisomant decreases endogenous 60 mg twice weekly). this regimen enabled growth hormone (GH) levels,” explains assessment of the dose at the final visit, adds van der lely. “also, for patients who lead investigator a. J. van der lely as well as the percentage of patients who need high-dose pegvisomant monotherapy, (erasmus mC, rotterdam). “also, the exhibited normalization of iGF-1 levels at a dose reduction of say 50%, for example, liver becomes selectively GH-resistant least once during the study period. from 200 mg to 100 mg per week, would via several mechanisms. therefore, the around 80% of patients had normalized save €40,000 per year.” as the mean market competitive GH receptor antagonist iGF-1 levels on at least one occasion. price of high-dose ssa monotherapy is pegvisomant meets less GH to compete although no head-to-head comparison around €20,000 per year in the eu, this with and needs to block less GH receptors was performed, the researchers confirmed reduction would notably reduce costs. in the liver in order to decrease insulin-like that a dose reduction of more than 50% Linda Koch growth factor 1 (iGF-1) levels.” in weekly pegvisomant can be expected van der lely and co-workers enrolled after a switch from monotherapy to Original article Van der Lely, A. J. et al. Coadministration 92 patients, who were biochemically combination therapy. of lanreotide Autogel® and pegvisomant normalizes IGF1 uncontrolled on ssas or on pegvisomant “as ssas are more effective in controlling levels and is well tolerated in patients with acromegaly monotherapy. all study participants tumor size, the combination might be more partially controlled by somatostatin analogs alone. Eur. J. entered a 4-month run-in period, in which attractive for patients with large tumors,” Endocrinol. doi:10.1530/EJE-10-0867